Adam Feuerstein

A conversation between @adamfeuerstein and @matthewherper about what Donald Trump's reelection could mean for biotech.

A conversation between @adamfeuerstein and @matthewherper about what Donald Trump's reelection could mean for biotech.

At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.

It’s time to correct one of the more egregious misconceptions about Cassava Sciences floating around the internet, @adamfeuerstein writes.

Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy for Duchenne muscular dystrophy.

The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their

On STAT's podcast, hear about what’s in store for biotech VCs in 2025, Pfizer's new head of R&D, drug innovation in a second Trump term, and more.

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.

I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many knew it would — with the company’s experimental drug for Alzheimer’s proving to be nothing more than a placebo in a clinical trial.